stacking tirzepatide with retatrutide GHK-Cu: Results & What to Expect Retatrutide vs Tirzepatide — What

This GLP-1 receptor agonist works primarily on the pancreas, brain, and gastrointestinal tract rather than the biliary system directly

doi: 10.1164/rccm.201910-1911tr 10

Many patients begin GLP-1 therapy with high hopes, only to find their weight loss plateaus or fails to materialize as advertised

The most common adverse events included nausea, affecting 38.1% to 43.2% of treated patients compared to 10.7% with placebo, diarrhea in 33.1% to 34.7% versus 13.4% with placebo, and constipation in 21.8% to 25% compared to 8.7% with placebo

Ozempic face is a non-medical term used to describe facial volume loss that can occur with rapid weight loss